These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29562224)

  • 1. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Al Hadidi S; Aburahma A; Badami S; Upadhaya S
    Oncol Res Treat; 2018; 41(4):226-235. PubMed ID: 29562224
    [No Abstract]   [Full Text] [Related]  

  • 2. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
    Lee EK; Konstantinopoulos PA
    Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
    J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
    Ray-Coquard I; Vanacker H; Le Saux O; Tredan O
    EBioMedicine; 2020 Nov; 61():103046. PubMed ID: 33038760
    [No Abstract]   [Full Text] [Related]  

  • 6. Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
    Lord R; Rauniyar J; Morris T; Condon O; Jones R; Miller R; Hall M; Lofts F; Glasspool RM; Hudson E
    Int J Gynecol Cancer; 2020 Jul; 30(7):1026-1033. PubMed ID: 32321768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
    Ray-Coquard I; Mirza MR; Pignata S; Walther A; Romero I; du Bois A
    Cancer Treat Rev; 2020 Nov; 90():102107. PubMed ID: 33099187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to sequence treatment in relapsed ovarian cancer.
    Pignata S; Cecere SC
    Future Oncol; 2021 Jan; 17(3s):1-8. PubMed ID: 33355013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice.
    Randall LM; Birrer MJ; Herzog TJ
    Oncologist; 2019 May; 24(5):576-579. PubMed ID: 30894410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    Washington C; Gunderson CC; Moore KN
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):4-11. PubMed ID: 30451713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
    Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
    Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
    Zhao Q; Ni J; Dong J; Cheng X; Xiao L; Xue Q; Xu X; Guo W; Chen X
    Reprod Sci; 2023 Feb; 30(2):615-621. PubMed ID: 35943701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.
    Lainé A; Sims TT; Le Saux O; Ray-Coquard I; Coleman RL
    Curr Oncol Rep; 2021 Nov; 23(12):148. PubMed ID: 34751835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
    Ibrahim EM; Refae AA; Bayer AM; Sagr ER
    Future Oncol; 2020 Apr; 16(10):585-596. PubMed ID: 32166978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.